Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00286481 · ClinicalTrials.gov registry record · Phase 3

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

A Phase 3 study, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
1,362
Enrollment target

NCT00286481: Completed Phase 3 study, sponsored by Takeda.

NCT00286481 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,362 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00286481, a Phase 3 study, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
1,362 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with simvastatin on cholesterol levels in treating patients with elevated cholesterol.

Interventions

  • DRUG Simvastatin
  • DRUG Lapaquistat acetate and simvastatin

Trial Details

FieldValue
Enrollment Target 1,362 participants
Start Date 2006-03
Est. Completion 2007-05
Phase Phase 3
Takeda

408 total trials

What the finished NCT00286481 record still lists

NCT00286481 is an interventional study that assigns participants to a tested intervention. Its 1,362 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% higher).

The record links to 0 conditions, and to 2 interventions - of which Simvastatin is the first listed.

NCT00286481 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00286481 about?

NCT00286481 is a clinical study titled "Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia". The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with simvastatin on cholesterol levels in treating patients with elevated cholesterol.

What is the current status of trial NCT00286481?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,362 participants. The study started on 2006-03. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00286481?

The interventions under investigation include: Simvastatin (DRUG), Lapaquistat acetate and simvastatin (DRUG).

Who is sponsoring clinical trial NCT00286481?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00286481's enrollment target sits among peer trials

1,362 180th of 2000 higher than 1,821 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02677064 · 1,365 participants

    Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

  • NCT04489238 · 1,366 participants

    Collection of Information to Better Understand Young Onset Colorectal Cancer

  • NCT05245227 · 1,358 participants · Phase 3

    Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

  • NCT07256392 · 1,370 participants · Phase 3

    Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00286481, the US trial registry maintained by the National Library of Medicine. NCT00286481 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.